Buzzkill Labs

Buzzkill Labs is a technology company that has developed a proprietary platform called ToxiTrace for rapid, on-site detection of psychoactive THC, the primary intoxicating compound in cannabis. Their patented oral fluid collection device, combined with chromatography-based analysis, offers employers and insurers a workplace safety solution by accurately identifying employees who have consumed cannabis during or immediately before work hours.

Buzzkill's technology addresses a critical gap in traditional drug testing methods, which often rely on urine samples and cannot differentiate between psychoactive THC and non-impairing compounds like CBD or THC metabolites. The ToxiTrace platform isolates and detects the psychoactive THC parent compound in saliva samples within 15 minutes, providing a reliable means to assess current impairment rather than past use.

In May 2023, Buzzkill announced the close of an oversubscribed Series A funding round co-led by Poseidon and existing investors. The company plans to use the proceeds to commercialize its technology, which aligns with the US Department of Transportation's updated drug testing policy to include oral fluid testing, published in May 2023.